Abstract
Abstract
Background
Chronic kidney disease (CKD) is highly prevalent in patients with coronary artery disease (CAD).
Objective
The outcome following revascularization using contemporary technologies (new-generation abluminal sirolimus-eluting stents with thin struts) in patients with CKD (i.e., glomerular filtration rate of < 60 mL/min/1.73m2) and in patients with hemodialysis (HD) is unknown.
Methods
e-Ultimaster is a prospective, single-arm, multi-center registry with clinical follow-up at 3 months and 1 year.
Results
A total of 19,475 patients were enrolled, including 1466 patients with CKD, with 167 undergoing HD. Patients with CKD had a higher prevalence of overall comorbidities, multiple/small vessel disease (≤ 2.75 mm), bifurcation lesions, and more often left main artery treatments (all p < 0.0001) when compared with patients with normal renal function (reference). CKD patients had a higher risk of target lesion failure (unadjusted OR, 2.51 [95% CI 2.04–3.08]), target vessel failure (OR, 2.44 [95% CI 2.01–2.96]), patient-oriented composite end point (OR, 2.19 [95% CI 1.87–2.56]), and major adverse cardiovascular events (OR, 2.34 [95% CI 1.93–2.83, p for all < 0.0001]) as reference. The rates of target lesion revascularization (OR, 1.17 [95% CI 0.79–1.73], p = 0.44) were not different. Bleeding complications were more frequently observed in CKD than in the reference (all p < 0.0001).
Conclusion
In this worldwide registry, CKD patients presented with more comorbidities and more complex lesions when compared with the reference population. They experienced higher rate of adverse events at 1-year follow-up.
Graphic abstract
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,General Medicine
Reference33 articles.
1. United States Renal Data System (2015) URDS annual data report: Epidemiology of Kidney Disease in the United States. National Institute of Health, National Institute of Diabetes and Digestive Kidney Disease: 2015 https://www.usrds.org/2017/download/2017_Volume_2_ESRD_in_the_US.pdf
2. Kramer A, Stel V, Zoccali C et al (2009) An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006. Nephrol Dial Transplant 24:3557–3566. https://doi.org/10.1093/ndt/gfp519
3. Liyanage T, Ninomiya T, Jha V et al (2015) Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 385:1975–1982. https://doi.org/10.1016/S0140-6736(14)61601-9
4. Jha V, Garcia-Garcia G, Iseki K et al (2013) Chronic kidney disease: global dimension and perspectives. Lancet 382:260–272. https://doi.org/10.1016/S0140-6736(13)60687-X
5. Astor BC, Hallan SI, Miller ER et al (2008) Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 167:1226–1234. https://doi.org/10.1093/aje/kwn033
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献